Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 33.73 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $72.788 million which missed the analyst consensus estimate of $79.323 million by 8.24 percent. This is a 91.76 percent increase over sales of $37.958 million the same period last year.